ABVC BioPharma, Inc.
- ABVC
- NASDAQ
- Biotechnology
- Clinical-Stage Drug Development
- Medical Device Development
$0.93
Today +2.20%Quote Oct 20, 2026, 08:00 PM UTC
−19.13%over the last month
Max drawdown −21.6%From 1-month high −19.8%3 months −21.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About ABVC BioPharma
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
18
Market value
$24.8M
Quote Oct 20
Floor
$0.86
7.3% below price
Resistance
$0.96
2.8% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ABVCPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free